Mechanism Investigation of Selinexor Combined With Lenalidomide and Rituximab in the Treatment of Diffuse Large B-cell Lymphoma

Launched by RUIJIN HOSPITAL · Jun 20, 2023

Keywords

ClinConnect Summary

This clinical trial is looking at how a combination of three medications—Selinexor, lenalidomide, and rituximab—can help treat patients with diffuse large B-cell lymphoma, a type of cancer affecting the lymphatic system. Researchers want to understand how these treatments work together and why some patients may not respond as well as others. They will collect samples from patients' blood and tumors before and after treatment to study the immune cells involved in the response to the therapy. This information could help improve treatment options for patients in the future.

To participate in this trial, you need to be at least 18 years old and have been diagnosed with diffuse large B-cell lymphoma that has either come back after treatment or has not responded to previous therapies. If you join, you’ll undergo treatment with the three medications mentioned and provide samples for research. The trial is not currently recruiting participants, but it aims to gather valuable data that could lead to better cancer treatments down the line.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. At least 18 years old.
• • 2. Histopathologically confirmed diffuse large B-cell lymphoma according to World Health Organization (WHO) classification criteria 2016.
• • 3. There is evidence of relapsed or refractory disease.
• • 4. Treatment with Selinexor combined with lenalidomide and rituximab.
• Exclusion Criteria:
• • No